Ceftazidime-avibactam activity against Escherichia coli and Klebsiella pneumoniae

头孢他啶-阿维巴坦对大肠杆菌和肺炎克雷伯菌的活性

阅读:2

Abstract

BACKGROUND AND OBJECTIVES: Carbapenem-resistant Enterobacteriaceae (CRE) infections are extremely difficult to treat and have a high fatality rate. The study's primary goal was to determine the rate of ceftazidime-avibactam susceptibility using disc diffusion and E-Test, as well as to evaluate the agreement between the two methods. MATERIALS AND METHODS: A total of 124 multidrug-resistant (including carbapenem) Escherichia coli and Klebisella pneumoniae isolates were included. Kirby Bauer's disc diffusion and E-test were used as the testing methods in this study. RESULTS: In this study 37.5% and 33.9% of the isolates were susceptible to ceftazidime-avibactam by E test and Disc diffusion respectively. There were five isolates which produced discordant results. Among the 56 isolates there was 91% agreement between the two methods. CONCLUSION: Among the discordant isolates the alarming disparity in zone size was a significant concern. Since CRE infections are very common, an economical and practical method for testing ceftazidime-avibactam susceptibility is needed in all the clinical microbiology laboratories as it is a last resort drug.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。